Unlike current treatments for AD, pharmacological inhibition of sEH focuses on reducing the neurodegenerative processes that trigger cognitive decline, neuroinflammation and, eventually, the clinical manifestations of dementia.23, 53. The gene discussed is EPHX2; the disease is Alzheimer disease.